Safety of onasemnogene abeparvovec for patients with spinal muscular atrophy 8.5 kg or heavier in a Global Managed Access Program

Authors

Deepa H Chand, Washington University School of Medicine in St. Louis
Susan Mitchell, Novartis Gene Therapies, Inc.
Rui Sun, Novartis Gene Therapies, Inc.
Nicole LaMarca, Novartis Gene Therapies, Inc.
Sandra P Reyna, Novartis Gene Therapies, Inc.
Thao Sutter, Novartis Gene Therapies, Inc.

Journal

Pediatric Neurology

Publication Date

7-1-2022

Volume

132

First Page

27

Last Page

32

Document Type

Open Access Publication

DOI

10.1016/j.pediatrneurol.2022.05.001

Rights and Permissions

Chand DH, Mitchell S, Sun R, LaMarca N, Reyna SP, Sutter T. Safety of Onasemnogene Abeparvovec for Patients With Spinal Muscular Atrophy 8.5 kg or Heavier in a Global Managed Access Program. Pediatr Neurol. 2022 Jul;132:27-32. doi: 10.1016/j.pediatrneurol.2022.05.001. © 2022 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Recommended Citation

Chand, Deepa H; Mitchell, Susan; Sun, Rui; LaMarca, Nicole; Reyna, Sandra P; and Sutter, Thao, "Safety of onasemnogene abeparvovec for patients with spinal muscular atrophy 8.5 kg or heavier in a Global Managed Access Program." Pediatric Neurology. 132, 27 - 32. (2022).
https://digitalcommons.wustl.edu/oa_4/1237

Additional Links

Supplemental material is available for this article at publisher site.